| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Shahrokh Shariat | Q7462263 |
| Marco Moschini | Q39051563 | ||
| Mohammad Abufaraj | Q39051577 | ||
| Francesco Soria | Q89184322 | ||
| Kilian M Gust | Q114316647 | ||
| P2093 | author name string | David D'Andrea | |
| P2860 | cites work | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Q30275266 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis | Q33433271 | ||
| Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract | Q34997941 | ||
| Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. | Q37873687 | ||
| Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. | Q38372019 | ||
| Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Q39107888 | ||
| Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. | Q41979947 | ||
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial | Q46287609 | ||
| Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 | ||
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial | Q47264823 | ||
| Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. | Q51356161 | ||
| Immune therapy meets precision medicine. | Q53455073 | ||
| Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study | Q57808395 | ||
| Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European | Q73881573 | ||
| Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy | Q86151894 | ||
| Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study | Q90987691 | ||
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | Q91729359 | ||
| Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma | Q92147555 | ||
| Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy | Q92249195 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 414-420 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Second line immune checkpoint inhibition in urothelial cancer | |
| P478 | volume | 8 |
Search more.